Bioelectronics Corp (BIEL)

[3331]

BIEL: The Old Book Is Now Closed - The New One Has Just Been Released and is Getting Rave Reviews!

1. The 2024–2025 (and Past) Financials Are Irrelevant!
Yes — 2025 revenue ticked up slightly to $510,623 from $496,032, and COGS dropped sharply from $132,633 to $77,276.
But here’s what matters:
These numbers reflect the pre Electrome, pre Haleon, pre-Veterinary era.
They are the last financials from the legacy “standalone device seller” model.
They have zero predictive value for the OEM future.
Why? Because BIEL is no longer a consumer gadget company — it is now the exclusive hardware engine for an AI native therapeutics ecosystem across human health, veterinary health, and global consumer health.
This is the “Intel Inside” transformation: Electrome AI = the brain. BIEL PEMF hardware = the engine.
The pivot just happened, so historical revenue is meaningless.

2. The OEM Future Is Measured in Millions — Not Thousands
The future is three independent OEM engines, each with multi million dollar trajectories:
OEM Engine #1 — Human Health (Electrome)
• PAINKILLER™ launch: $0.75M–$2.25M
• AI expansion: $4M–$7M
• National penetration: $7.5M–$22M annually
OEM Engine #2 — Veterinary AI
• Elite performance animals: $500K–$1.2M
• Specialty clinics: $3M–$7.5M
• Global pet wearables: $12M–$25M+ annually
OEM Engine #3 — Haleon (Global Consumer Health)
• Retail pilots: $2M–$5M
• Global rollout: $15M–$35M
• Mass market wearables + subscriptions: $50M–$100M+ annually
These are not projections for 2035. These are phase-based rollouts already in motion.
Compared to this, the 2024–2025 financials are rounding errors.

3. Capital Factory Validation Makes the Past Irrelevant
Electrome is backed by Capital Factory, one of the most respected early stage VC groups in the U.S. Their involvement signals:
• The tech is real
• The platform is scalable
• The hardware dependency on BIEL is locked in
Microcaps almost never get this halo. BIEL did.
Once institutional validation enters the picture, historical micro revenues no longer matter — future cash flows do.

4. The Float, Momentum, and AI Narrative Are Re Rating Catalysts
BIEL is gaining momentum and it’s getting stronger:
• A historic 400% run from .0001 to .0005
• A vanishing float
• A pending supply squeeze
This is the exact configuration that precedes violent re ratings in microcaps.
And the AI narrative is the accelerant:
Electrome turns BIEL into a hot sector AI hardware play.
This is why the market will price the future, not the past.

5. Profitability Is Within Reach — And the Model Is Ultra Lean
BIEL already demonstrated profitability before:
• Q3 2021 profit: $22,381 on $414,700 revenue
With COGS now dramatically lower and OEM volumes rising, the path to sustained profitability is short.
And the $40M tax loss carryforward accelerates net profit conversion .

6. PPS Re-Rating Scenarios Make the Past Financials Meaningless
PPS for corresponding milestones:
• .001 — Technical breakout (Blue Sky Breakout)
• .01 — Cash flow positive (about $1.5M annual rev)
• .04 — $1M profit (est rev = $1.5M rev, P/E 1000)
• .10 — $2.5M profit (est rev = $3M rev, P/E 1000)
• $1.00 — After debt payoff + stock buyback
These valuations are based on future OEM profit, not legacy device sales.

CONCLUSION: The 2024–2025 (and Past) Financials Don’t Define BIEL — They Are the Last Pages of the Old Story
The new story is:
• AI native therapeutics
• Multi industry OEM dominance
• VC validation
• Global consumer health integration
• Veterinary expansion
• Recurring hardware nodes
• A closed loop ecosystem

BIEL is no longer a $500K revenue company. It is a future multi vertical OEM engine with $100M+ annual potential across its combined channels. The past is irrelevant (as are the posters that dwell on it)! The future starts now, and it’s asymmetric! What makes this setup even more asymmetric is that BIEL is, functionally, a startup without startup risk — the company already has five FDA clearances, a fully validated manufacturing pipeline, and venture capital backing through Electrome, yet carries none of the typical burn rate, R&D overhead, or regulatory uncertainty that normally crush early stage companies.

Instead of spending $50M–$100M on development, trials, and approvals, BIEL enters the OEM era with all of that already done — and with high value patents pending, including the vagus nerve modulation patent that could open entirely new therapeutic markets. This is the rare case where a microcap has the regulatory moat, the IP pipeline, and the VC funded commercialization engine before the revenue inflection even begins.